Tuesday, May 5, 2026
← Back to archivePolicy
Policy•Fierce Biotech•May 4, 2026
Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA
background ▾
- •FDA's CBER rejected single-arm trial for PBFT02 despite rare disease indication and robust natural history data, mandating RCT for registration—a decision now threatening company viability
- •This reflects systemic FDA skepticism toward single-arm designs for gene therapies under former CBER director Vinay Prasad (now departed); regulatory leadership change may create opportunity for reconsideration
- •Monitor: Whether Passage can negotiate alternative trial designs with new CBER acting director Katherine Szarama, and whether strategic review yields acquisition or partnership that salvages PBFT02 program
Passage BiouniQureReplimunePBFT02
→ Read original articlePolicy•KFF•May 4, 2026
Health Coverage by Race and Ethnicity, 2010-2024
background ▾
- •Projected 14+ million increase in uninsured Americans by 2034 due to Medicaid cuts and ACA premium tax credit expiration, with disparate impact on racial and ethnic minorities
- •Racial and ethnic disparities in coverage have persisted or widened since 2010 despite earlier ACA gains, with American Indian/Alaska Native and Hispanic populations facing uninsured rates 2.7–2.8 times higher than White populations
- •Pharmaceutical companies and health systems should anticipate reduced medication access and adherence challenges in minority populations; payers and manufacturers may need to adjust patient support programs and pricing strategies to address widening health equity gaps
Policy•KFF•May 5, 2026
What AI Can Do — And What It Can’t
background ▾
- •Industry veteran with 30+ years of experience observes that foundational conditions for AI success may finally exist (data, technology, compute, clear use cases), but expresses measured skepticism given history of unfulfilled digital health promises
Mayo ClinicBeth Israel Deaconess Medical CenterBeth Israel Lahey Health
→ Read original articlePolicy•Fierce Biotech•May 4, 2026
‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and China
background ▾
- •FDA's current CMC requirements for phase 1 programs are economically prohibitive for small biotechs and are driving first-in-human trials to China and Australia, where regulatory pathways are faster and cheaper
- •Phase 1 costs per patient have increased 4-8x in recent years (from $50-100k to $400k+), and total IND development costs have more than doubled from $9M to $20M+, primarily driven by manufacturing and stability requirements
- •The competitiveness metric in biotech has shifted to speed of first-in-human data generation; regulatory modernization and small-scale manufacturing capacity rebuilding are urgent industry-government priorities
Strand Therapeutics
→ Read original articlePolicy•Fierce Pharma•May 5, 2026
After March cuts, Novartis trims another 60 roles at US headquarters
background ▾
- •Novartis is cutting 60 additional U.S. headquarters roles, building on 114 cuts announced in March, as part of a multiyear restructuring program
Novartis
→ Read original articleMarket Access
Market Access•Fierce Biotech•May 4, 2026
UCB inks $2B Candid buyout to join Gilead in autoimmune field
background ▾
- •UCB acquires Candid for $2B to secure a late-stage BCMAxCD3 TCE (cizutamig) with phase 1 evidence of deep B-cell depletion and tolerability in autoimmune patients, directly competing with Gilead's acquisition of Ouro Medicines.
- •Cizutamig demonstrated predominantly low-grade, manageable CRS in 68 autoimmune patients with phase 1 data supporting phase 2 initiation planned for mid-2026 in myasthenia gravis and ILD—a critical safety profile advantage for outpatient TCE therapy.
- •Watch for phase 2 readouts of cizutamig and Ouro's BCMAxCD3 programs in 2026-2027, clinical data from Cullinan/Genrix's competing BCMAxCD3 asset expected late 2024, and whether other pharma players enter the TCE-for-autoimmune race.
UCBCandid TherapeuticsGilead SciencescizutamigCND261
→ Read original articleMarket Access•STAT News•May 4, 2026
UCB to acquire maker of antibody treatments for autoimmune diseases
background ▾
- •UCB's $2.2B acquisition of Candid Therapeutics reflects major pharma's confidence in bispecific antibody platforms for autoimmune disease, particularly B-cell depletion via immune reset mechanisms as differentiated from current standard-of-care
- •Candid's portfolio was built via licensing deals with Chinese biotechs; the acquisition occurs amid tightening U.S.-China biotech competitive dynamics and new Chinese industrial security decree (Decree 834) that could reshape global pharma supply chain and IP strategy
- •Monitor clinical progression of Candid's lead bispecific antibody program and competitive response from other autoimmune developers pursuing similar B-cell targeting and immune reset strategies
UCBCandid TherapeuticsBristol Myers SquibbCandid's lead bispecific antibody (BCMA-targeting)
→ Read original articleMarket Access•Fierce Pharma•May 5, 2026
CDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike
background ▾
- •Samsung Biologics faces a $102 million financial hit from strike-related production adjustments, signaling real operational and financial consequences for a major CDMO serving multiple pharma clients
- •Preemptive production adjustments suggest Samsung is attempting to maintain client commitments despite labor disruptions, but with measurable cost to the company
Samsung Biologics
→ Read original articleMarket Access•Fierce Pharma•May 5, 2026
Bristol Myers Squibb ties science to soccer in World Cup campaign voiced by Ali Krieger
background ▾
- •BMS is using sports sponsorship and celebrity endorsement for consumer brand building rather than disease awareness or direct-to-consumer drug promotion
Bristol Myers Squibb
→ Read original articleMarket Access•Fierce Pharma•May 5, 2026
Amgen channels another $300M into US outlay, bolstering Puerto Rico biologics expansion
background ▾
- •Amgen's sustained capital commitment ($300M additional) to Puerto Rico demonstrates strategic emphasis on nearshoring and U.S.-based biologics manufacturing resilience.
Amgen
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•May 4, 2026
Takeda pivotal trial win improves convenience for PID patients relative to HyQvia
background ▾
- •TAK-881 achieved equivalent IgG exposure to HyQvia (geometric mean ratio 99.67%) with half the infusion volume and shorter infusion times, addressing a key unmet need in PID patient convenience
- •Trial included broader population (ages 2+) compared to HyQvia's approved age range (16+), potentially supporting a label extension opportunity for pediatric patients
- •Regulatory filings expected in fiscal 2026 (ending March 2027); success would strengthen Takeda's plasma-derived therapies franchise and direct competition with its own HyQvia franchise
TakedaHalozymeTAK-881HyQvia
→ Read original articleClinical Trials•Fierce Biotech•May 4, 2026
Mirum maps FDA path after anti-itch candidate scores ph. 2 win
background ▾
- •Volixibat demonstrated clinically meaningful superiority over placebo in PSC pruritus (2.72 vs. 1.08 point reduction), supporting FDA filing pathway in H2 2024 with NDA meeting planned for summer 2024
- •Elevated liver enzyme and bilirubin levels in volixibat-treated patients raise safety signals that require independent assessment before regulatory submission; 9.1% discontinuation rate due to adverse events is substantially higher than placebo (2.5%)
- •PSC remains an unmet medical need with no FDA-approved therapies; volixibat's potential approval could capture significant market share, though Mirum faces indirect competition from GSK's Lynavoy (recently approved for PBC)
Mirum PharmaceuticalsGSKAlfasigmavolixibatLivmarliLynavoy
→ Read original articleClinical Trials•Fierce Biotech•May 4, 2026
Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study
background ▾
- •Phase 3 Viktoria-1 hit primary endpoint for gedatolisib in PIK3CA-mutant breast cancer with superior PFS versus Piqray-based comparator, enabling supplemental FDA filing after initial wild-type submission
- •Gedatolisib showed improved tolerability profile versus Piqray on hyperglycemia but carries safety signals around stomatitis that will influence clinical uptake and peak sales potential ($2.1B by 2032 forecasted)
- •Detailed phase 3 data presentation at ASCO 2026 will be critical for market positioning; late-breaking abstract inclusion suggests meaningful clinical benefit magnitude
CelcuityNovartisAstraZenecagedatolisibPiqrayFaslodex
→ Read original articleClinical Trials•Fierce Biotech•May 4, 2026
Vertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues
background ▾
- •VX-522 discontinued due to persistent lung inflammation linked to lipid nanoparticle formulation—a foundational delivery challenge for inhaled mRNA therapeutics that could affect similar programs industry-wide
- •The failure eliminates Vertex's only inhaled approach for CFTR gene therapy and raises questions about mRNA-LNP tolerability in pulmonary delivery, a modality Moderna positioned as differentiated
- •Watch for: Vertex's alternative delivery strategy announcements for CFTR gene therapy; Moderna's broader inhaled mRNA pipeline status and any pivots in formulation chemistry; competitive positioning by other CF gene therapy developers (e.g., CRISPR, bluebird bio)
Vertex PharmaceuticalsModernaVX-522mRNA-3692
→ Read original articleClinical Trials•Fierce Biotech•May 4, 2026
Windward catches $165M breeze to fuel long-acting TSLP ambitions
background ▾
- •WIN378's twice-yearly dosing schedule represents a potential competitive advantage over Tezspire (once-monthly) in a high-value indication, pending phase 3 efficacy and safety confirmation
- •Windward's rapid ascent from January 2025 launch with $200M Series A to $165M crossover financing, combined with Sanofi Ventures participation, signals strong investor confidence despite a crowded anti-TSLP market
- •Watch for WIN378 phase 2 dose-ranging readout imminently and phase 3 initiation in Q4 2026; also monitor WIN027 (TSLPxIL-13 bispecific) proof-of-concept data in respiratory and dermatology given Sanofi's mixed results with similar mechanism
Windward BioOrbiMedRA Capital ManagementWIN378WIN027Tezspire
→ Read original article